EN | DE

Biosimilars differentiated by innovative injection technology

FINOX-Biotech develops Biosimilars and combines them with specifically designed injection technologies. By this we positively differentiate our combination-products compared to the reference products.

With our biosimilars, we want to create value for patients, partners and our investors:
 
  • for patients - with safe, efficient, easy to administer and fairly priced treatment of the highest quality.
     
  • for partners and investors - based on reciprocity, transparent business.
FINOX-Medtech develops injection technology for subcutaneous, intravenous or intramuscular administration of liquid medications for the Life Science Industry. Our injection technologies are differentiated by their simple and safe - thus compliance-promoting - handling.

Partnerships:
FINOX is looking for interesting partnerships, both in the field of Biosimilars and for the marketing of our injection technologies - contact us!

FINOX was founded 2007 in Switzerland and has since been working on implementing the vision.